# Dose Calibrator Geometry

**INVIVO Coach 002**
101 Dillon Court  
Gray, TN, 37615  
R-90053-K20  

<table>
<thead>
<tr>
<th>Volume</th>
<th>Assayed Time</th>
<th>Assayed Activity</th>
<th>Decay Correction</th>
<th>Correction Factor %</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.5</td>
<td>12:26</td>
<td>31.8</td>
<td>38.086</td>
<td>0</td>
</tr>
<tr>
<td>1</td>
<td>12:27</td>
<td>31.4</td>
<td>37.534</td>
<td>-1.274</td>
</tr>
<tr>
<td>1.5</td>
<td>12:28</td>
<td>31.4</td>
<td>37.46</td>
<td>-1.274</td>
</tr>
<tr>
<td>2</td>
<td>12:29</td>
<td>31</td>
<td>36.915</td>
<td>-2.581</td>
</tr>
<tr>
<td>2.5</td>
<td>12:30</td>
<td>31.1</td>
<td>36.962</td>
<td>-2.251</td>
</tr>
<tr>
<td>3</td>
<td>12:31</td>
<td>30.8</td>
<td>36.534</td>
<td>-3.247</td>
</tr>
</tbody>
</table>

Test results must fall within +/- 10% NRC/STATE Trigger Limit to PASS.

**TEST RESULTS:** All results within 10%

**Notes:**

**TEST DATA:**

Performed by:  
Blaine J Beining  
Technical Director  
Licensee: INVIVO Coach 002  
Registration: R-90053-K20  

Report Printed: 5/30/2013 12:31:53 PM
**Dose Calibrator Geometry**

**INVIVO Coach 002**

101 Dillon Court
Gray, TN, 37615

R-90053-K20

---

**Dose Calibrator:** Dose Calibrator

**Normalization Activity (mCi):** 31.3

**Container Used:** Syringe

---

<table>
<thead>
<tr>
<th>Volume</th>
<th>Assayed Time</th>
<th>Assayed Activity</th>
<th>Decay Correction</th>
<th>Correction Factor %</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.5</td>
<td>12:44</td>
<td>31.3</td>
<td>36.215</td>
<td>0</td>
</tr>
<tr>
<td>1</td>
<td>12:46</td>
<td>30.7</td>
<td>35.382</td>
<td>-1.954</td>
</tr>
<tr>
<td>1.5</td>
<td>12:47</td>
<td>30.7</td>
<td>35.317</td>
<td>-1.954</td>
</tr>
<tr>
<td>2</td>
<td>12:48</td>
<td>30.6</td>
<td>35.133</td>
<td>-2.288</td>
</tr>
<tr>
<td>2.5</td>
<td>12:50</td>
<td>30.6</td>
<td>35</td>
<td>-2.288</td>
</tr>
<tr>
<td>3</td>
<td>12:51</td>
<td>30.5</td>
<td>34.817</td>
<td>-2.623</td>
</tr>
<tr>
<td>3.5</td>
<td>12:52</td>
<td>30.4</td>
<td>34.635</td>
<td>-2.961</td>
</tr>
<tr>
<td>4</td>
<td>12:53</td>
<td>30.4</td>
<td>34.571</td>
<td>-2.961</td>
</tr>
<tr>
<td>4.5</td>
<td>12:54</td>
<td>30.3</td>
<td>34.39</td>
<td>-3.3</td>
</tr>
<tr>
<td>5</td>
<td>12:55</td>
<td>30.2</td>
<td>34.21</td>
<td>-3.642</td>
</tr>
</tbody>
</table>

**Source:** 864141

**Container Size:** 5

---

Test results must fall within +/-10% NRC/STATE Trigger Limit to PASS.

**TEST RESULTS:** All results within 10%

**Notes:** Allan drew the volumes & Blaine Recorded in BioDose

---

**TEST DATA:**

Performed by: Blaine J. Beining

Technical Director

Licensee: INVIVO Coach 002

Registration: R-90053-K20
Memorandum of Understanding

This memorandum of understanding (hereafter referred to as MOU) is an agreement entered into by Beckley Appalachian Regional Healthcare (hereafter referred to as ARHB) located at 300 Stonyford Rd, Beckley, WV 25801 and Diagnostic Laboratories D.B.A. Invivo Molecular Imaging LLC. (hereafter referred to as IM), located at 101 Dillon Court, Gray Tennessee, 37615. The purpose of this MOU is to delineate the authority and responsibility of each party for administration and use of radioactive materials, more specifically, Positron Emission Tomography (PET) related drugs. This memorandum of understanding shall apply during any contracted terms for imaging services between ARHB and IM.

By signing this memorandum ARHB is hereby authorizing IM to perform radioactive material imaging studies on its campus, at the above mentioned address for the duration of any contracted services with IM.

Administration of radiopharmaceuticals: While this contract is in effect it will be the responsibility of IM to administer all radiopharmaceuticals in accordance with the site Authorized User’s standard dose protocol.

Receipt and Disposal of Radioactive Materials: IM will have sole responsibility for the receipt and disposition of all radioactive material used in or pursuant to imaging on its mobile coach. No radiopharmaceuticals will be delivered to ARHB. The only exception to this rule will be the sanitary facilities for patient use. It will be the responsibility of ARHB to provide a suitable sanitary facility for patient use prior to/pursuant to imaging. Also, ARHB will be responsible for the radiation protection aspects of this area and compliance with any and all applicable radiation or environmental regulations as prescribed by Nuclear Regulatory Commission.

Authorized User (AU): It will be the responsibility of ARHB to provide an AU for the ordering of all radiopharmaceuticals. Furthermore, it will be responsibility of ARHB to ensure that these physicians are properly licensed by the Nuclear Regulatory Commission.
**Radiation Protection Program:** IM will maintain control of the radiation protection program inside the mobile coach. IM's Radiation Safety Officer will be responsible for ensuring compliance with all license conditions set forth in IM's Nuclear Regulatory Commission Radioactive Materials License.

**Compliance with Radiation Doses to the Public:** It will be the responsibility of IM to ensure that radiation levels around the mobile coach are at or below those levels set forth in the Nuclear Regulatory Commission's regulations. Also, IM will maintain proper and calibrated radiation detection equipment for this purpose.

**Personnel Dosimetry:** IM will be responsible for monitoring the radiation doses to its own staff. ARHB will not need to provide and radiation monitoring or oversight.

**Radiation Safety Training:** IM will provide radiation safety training to its staff in accordance with their Nuclear Regulatory Commission radioactive materials license. General site specific safety training will be provided by ARHB to IM staff, so that they may familiarize themselves with any hospital specific policies.

---

**Diagnostic Laboratories**  
D.B.A. Invivo Molecular Imaging LLC.

---

**Jennifer Y. Bailey, BSN RN 5/08/13**  
Beckley Appalachian Regional Healthcare  
Date